Vasopressin vs Norepinephrine: How the Two Vasopressors Differ

Two different molecules used for the same clinical problem

Norepinephrine is a catecholamine, not a peptide. Vasopressin is a 9 amino acid peptide hormone. That single structural difference explains most of what follows: the two drugs bind entirely different receptor families, produce partly different cardiovascular and renal effects, and carry different adverse event profiles in published trials. Both are prescription medicines given as continuous intravenous infusions in intensive care units, and both are discussed together because reviews of vasopressor therapy in shock describe norepinephrine as the agent most often used first and vasopressin as an agent studied mainly in an adjunctive or alternative role (PMID 31646370).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. It contains no doses, no infusion rates and no treatment guidance, because vasopressor selection, titration and weaning in shock are decisions made by a treating critical care team at the bedside.

For background on the peptide itself, see vasopressin and how vasopressin works. For a comparison between vasopressin and its longer acting analogue, see vasopressin vs terlipressin.

Mechanism: V1 receptors versus adrenergic receptors

Vasopressin and the V receptor family

Vasopressin is the synthetic counterpart of the endogenous posterior pituitary hormone also known as antidiuretic hormone. Its vascular effect is mediated chiefly by V1a receptors on vascular smooth muscle, which couple to Gq proteins and the phospholipase C pathway to raise intracellular calcium and produce vasoconstriction. Separate V2 receptors in the renal collecting duct govern water reabsorption, and V1b receptors in the anterior pituitary participate in corticotroph signalling. Reviews of vasopressor pharmacology group vasopressin with the non catecholamine vasoconstrictors precisely because it does not act on adrenergic receptors at all (PMID 32820475).

Norepinephrine and the adrenergic receptors

Norepinephrine is an endogenous catecholamine neurotransmitter and hormone. It is a potent alpha 1 adrenergic agonist, producing arterial and venous constriction, with meaningful beta 1 activity that adds modest inotropic support and relatively little beta 2 mediated vasodilation. Reviews of vasopressor therapy in critically ill patients describe this combined alpha and beta profile as the reason norepinephrine raises mean arterial pressure while generally preserving or increasing cardiac output (PMID 31646370).

Why the difference matters pharmacologically

Because the two agents act on separate receptor systems, their effects are not simply interchangeable. The adrenergic pathway is the target of catecholamines generally, and comparative trials within that class have shown that receptor profile influences adverse events: in a randomised trial of 1679 patients with shock, researchers compared dopamine with norepinephrine and reported no significant difference in 28 day mortality but a higher rate of arrhythmic events in the dopamine group (PMID 20200382). Vasopressin sits outside that class entirely, which is the conceptual basis for studying it as an agent added alongside a catecholamine rather than as another version of one (PMID 32820475).

Side by side comparison

What the head to head septic shock trials reported

VASST

The Vasopressin and Septic Shock Trial randomised 778 adults with septic shock who were already receiving catecholamine support to receive either low dose vasopressin or norepinephrine in a blinded fashion, and researchers reported no significant difference in 28 day mortality between the two groups (PMID 18305265). In a prespecified stratified analysis, the study reported lower mortality with vasopressin among patients in the less severe shock stratum, a subgroup observation the authors treated as hypothesis generating rather than definitive (PMID 18305265).

VANCS II

The VANCS II randomised clinical trial compared vasopressin with norepinephrine as the initial vasopressor for septic shock specifically in patients with cancer, and researchers reported no significant difference in the primary mortality endpoint between the two agents (PMID 31609774). That trial is frequently cited alongside VASST because it tested the comparison in a population with distinct baseline risk rather than in a general medical and surgical intensive care population (PMID 31609774).

What the pooled analyses and reviews reported

An individual patient data meta-analysis of randomised controlled trials of vasopressin in septic shock pooled trial level patient data and reported no clear mortality benefit for vasopressin, while examining secondary signals including the use of kidney replacement therapy and the occurrence of digital ischaemia (PMID 31062052). A systematic review and network meta-analysis of vasopressors for septic shock pooled randomised evidence across several agents and combinations, and researchers reported comparative estimates for both efficacy and safety endpoints rather than identifying one agent that outperformed all others on every outcome (PMID 37548686).

Narrative reviews of vasopressor therapy summarise the same pattern: norepinephrine is described as the usual first agent, and non catecholamine vasoconstrictors including vasopressin are described as options studied for catecholamine sparing effects and for situations where adrenergic agents alone are insufficient (PMID 31646370, PMID 32820475).

Timing of vasopressin addition

A 2025 target trial emulation using observational intensive care data examined earlier versus later initiation of adjunctive vasopressin in patients with septic shock already receiving norepinephrine, and researchers reported that the timing of initiation was associated with differences in outcome while noting that emulation methods cannot substitute for randomisation (PMID 40355911).

Order of discontinuation

A separate question is which agent is removed first when shock resolves. A meta-analysis addressing that question pooled studies of patients receiving both agents and reported a higher incidence of clinically significant hypotension when vasopressin was discontinued before norepinephrine (PMID 31008869). The authors of that analysis framed the finding as a signal from mostly observational data rather than as a settled answer (PMID 31008869).

Adverse Events: What Studies Report

Adverse event reporting differs between the two agents because the receptor targets differ.

• Digital and peripheral ischaemia. The individual patient data meta-analysis of vasopressin trials in septic shock examined ischaemic adverse events and reported digital ischaemia among the harms associated with vasopressin exposure in the pooled randomised data (PMID 31062052).
• Arrhythmia. Arrhythmic events are the classic concern with adrenergic agents, and the randomised comparison of dopamine with norepinephrine in 1679 patients with shock reported significantly more arrhythmic events in the dopamine arm (PMID 20200382).
• Mortality endpoints. Neither VASST nor VANCS II reported a statistically significant mortality difference between vasopressin and norepinephrine in their primary analyses (PMID 18305265, PMID 31609774).
• Kidney outcomes. Kidney replacement therapy has been a recurring secondary endpoint, examined in the pooled vasopressin trial data (PMID 31062052) and separately in a 2025 analysis of hydrocortisone and risk factors for kidney replacement therapy in septic shock (PMID 40423970).

Why the comparison remains unsettled

Septic shock is not one disease, and that is part of why head to head vasopressor trials have produced neutral primary results. A 2025 consensus blood transcriptomic framework for sepsis described reproducible molecular subgroups across patient cohorts, and researchers presented that framework as a step toward resolving biological heterogeneity that conventional clinical trial enrolment criteria do not capture (PMID 41028542). Adjunctive strategies beyond vasopressors have been tested in the same population; for example, a randomised controlled trial of early adjunctive methylene blue in septic shock reported a shorter time to vasopressor discontinuation in the methylene blue group compared with placebo (PMID 36915146).

Taken together, the published literature supports a factual summary rather than a ranking: the two agents differ in structure and receptor target, randomised head to head comparisons have not demonstrated a mortality advantage for vasopressin over norepinephrine in septic shock (PMID 18305265, PMID 31609774), and pooled analyses continue to examine secondary endpoints and harms (PMID 31062052, PMID 37548686). These are hospital infusions administered under continuous monitoring, and the choice between them belongs to the treating clinicians.

Related reading

• Vasopressin: peptide overview
• How does vasopressin work
• Vasopressin vs terlipressin

References

• Vasopressin versus norepinephrine infusion in patients with septic shock (The New England Journal of Medicine, 2008)
• Comparison of dopamine and norepinephrine in the treatment of shock (The New England Journal of Medicine, 2010)
• Vasopressor therapy in critically ill patients with shock (Intensive Care Medicine, 2019)
• Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials (Intensive Care Medicine, 2019)
• Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial (Critical Care Medicine, 2019)
• Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis (Shock, 2020)
• Vasopressor Therapy in the Intensive Care Unit (Seminars in Respiratory and Critical Care Medicine, 2021)
• Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial (Critical Care, 2023)
• The efficacy and safety of vasopressors for septic shock patients: a systemic review and network meta-analysis (Shock, 2023)
• Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation (Critical Care, 2025)
• Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock (JAMA Network Open, 2025)
• A consensus blood transcriptomic framework for sepsis (Nature Medicine, 2025)